Metals have been used in clinical practice for hundreds of years and for a variety of in(lications. Although potent agents whose activity may be adapted by manipulation of their chemistry and that of associated ligands, their use has been limited by toxic effects. There is now a burgeoning series, of delivery technologies available which may be adapted to the administration of metal base d drug,. Together with greater understanding of metal chemistry and their mechanisms of action in disea'se processes, there is an opportunity to increase the use of metals in medicine by targeting their action more effectively to the therapeutic site and/or protecting the body from toxic effects..
Introduction
Metals have been used in medicine for hundreds of years. Most common delivery methods were via the oral route and topical application. Indications ranged from the treatment of syphilis witlt arsenic or mercury to Chinese herbal remedies which contained lead, mercury and arsenic amon.c. others .
Populations have also been exposed to metals through their use in agriculture, for insta'nce the use of mercury as a fungicide on seed corn which led to many deaths in the early 1980's in Iraq when food shortages led to the use of seed grain to make bread despite Government warni'ngs.
There are still many areas of clinical application where metals make a signific'.nt contribution. Examples would include the use of platinum (cancer chemotherapy), mercury (rJental amalgams), gold (Rheumatoid Arthritis), Silver (wound healing), Technetium (imaging), Ircn supplements) and so on. A general theme evident in the use of metals in medicine throughout history is the balance of efficacy with respect to the target biochemical system and the potential for immediate or long term toxicity. This paper seeks to explore the delivery means that are cu'rently available or in development that may assist in retaining activity at the target site while reducin g the toxicity of metal- An alternative strategyis to encase the metal complex Within an external structure such as a liposome, constructed of polar lipid molecules, or proteinoids, hollow microspheres of condensed amino-acids. This strategy could enhance absorption, potentially reduce toxicity and protect the active moiety from deactivation before it reached the target site. Wrapping technologies are able to protect the active agent through the processes of absorption and distribution. They involve embedding the drug within a matrix whose physicochemical properties can be adjusted to suit the properties of the compound and the chosen delivery route. At present the only liposome-based marketed products are indicated for systemic fungal and mycobacterium infections and for dermatological use. However products are in development for use as cancer chemotherapeutic agents.
An alternative means of protecting the active molecule could make use of a pro-drug approach, whereby biochemical processes within the body modify the formulation to release the active form. Again, challenges to be overcome would most likely arise from technical issues with respect to initial manufacture of a reproducible formulation and consistent release of the therapeutic agent at the site of action.
Several of the established routes of administration could be used for the above strategies. Oral formulations represent the majority of novel drug .delivery systems a and carrier based strategies are available to increase the bioavailability of high molecular weight compounds or complexes. The use of the oral route can provide opportunities to tailor the kinetics of the product, including the onset time of drug release, or if appropriate the site of absorption within the gastrointestinal tract.
Inhalation technology is now able to deliver therapeutic levels of high molecular weight compounds at low inspiration rates using propellant-free devices. The deep lung has a large surface area for drug delivery and constitutes an opportunity for rapid delivery of compounds capable of being formulated in dry powder form. In summary, the challenge for the future development of metals in clinical practice is to improve current means of delivery where metals are of known benefit, to identify additional therapeutic uses of metals in medicine and to link potential uses of metals to enabling technologies. The recent development of innovative means of delivery for pharmaceuticals of various molecular weights and physiochemical characteristics has introduced an opportunity to expand the use of metals in medicine. By imaginative construction of desired product profiles and close collaboration between chemists, physicians and delivery technology specialists it will be feasible to construct formulations that will make best use Of the potency of metals while improving their safety profile.
